Vitruvias Therapeutics Recalls Superpotent Thyroid Tablets Nationwide

Vitruvias Therapeutics Inc. announced a nationwide recall of one lot of its 30 mg thyroid tablets due to potential superpotency, which could trigger hyperthyroidism symptoms, according to a Food and Drug Administration (FDA) notice on August 24, 2026.

The recalled lot, number 504950, was distributed across the United States from January 31, 2025, to September 30, 2025, with an expiration date set for September 30, 2026. About 3,655 units were released, and approximately 1,955 units were sold, the company reported.

Consumption of superpotent thyroid tablets can cause an overactive thyroid, leading to symptoms such as weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, and irregular heart rhythms.

Vitruvias Therapeutics stated, "Consumption of super potent thyroid tablets can cause hyperthyroidism, or an overactive thyroid, bringing a slew of symptoms such as weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate or heart rhythm disturbances."

The company emphasized that elderly individuals, pregnant women, and infants are particularly vulnerable to these effects if the medication is taken over extended periods.

In its recall alert, Vitruvias Therapeutics also advised, "Patients who have the recalled lot should not discontinue use without contacting their healthcare provider."

The recalled product, labeled as Thyroid Tablets, USP 30 mg, contains levothyroxine and liothyronine and is used to treat hypothyroidism or an underactive thyroid.

According to the FDA, "People who are currently using the recalled medication should not stop using it until they have consulted with a healthcare provider for guidance."

Vitruvias Therapeutics confirmed it has not received any reports of adverse reactions linked to the recall as of the announcement date. It is contacting wholesalers to halt distribution and arrange the destruction of all recalled units.

Consumers with questions about the recall can reach Vitruvias Therapeutics by email at [email protected] or by phone at (256) 239-9373, Monday through Friday from 9 a.m. to 5 p.m. Central Time.